Promethera Biosciences   Report issue

For profit Phase 2
Founded: Mont-Saint-Guibert Belgium (2009)

Organization Overview

First Clinical Trial
2012
NCT01765283
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Promethera Biosciences

Active Ingredients

Drugs in Phase 2 Trials (3)

Key: Promethera Biosciences (2) Acquired (1)

hepastem (2 trials)

heterologous human adult liver-derived progenitor cells (3 trials)

human heterologous liver cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute-On-Chronic Liver Failure (Phase 2)

Cardiomyopathies (Phase 2)

Crigler-Najjar Syndrome (Phase 2)

Disease (Phase 2)

End Stage Liver Disease (Phase 2)

Fatty Liver (Phase 2)

Hepatic Insufficiency (Phase 2)

Liver Failure (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Syndrome (Phase 2)

Urea Cycle Disorders, Inborn (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 3